Maternal RSVpreF Vaccination Shows 78% Effectiveness Against Infant RSV Hospitalization in Real-World Data

A systematic review and meta-analysis of seven real-world studies, published in JAMA Pediatrics, found that maternal vaccination with the respiratory syncytial virus (RSV) bivalent prefusion F protein vaccine (RSVpreF; Abrysvo) was 78% effective against RSV-associated lower respiratory tract infection (LRTI) hospitalization in infants from birth to 6 months of age. This effectiveness was observed when the vaccine was administered at least 14 days before delivery. The findings support the integration of RSVpreF into routine antenatal immunization programs to protect vulnerable newborns.